IMRX logo

IMRX
Immuneering Corp

2,939
Mkt Cap
$348.16M
Volume
423.00
52W High
$10.08
52W Low
$1.10
PE Ratio
-3.87
IMRX Fundamentals
Price
$5.34
Prev Close
$5.39
Open
$5.45
50D MA
$5.33
Beta
1.37
Avg. Volume
785,471.96
EPS (Annual)
-$1.27
P/B
1.58
Rev/Employee
$0.00
$120.59
Loading...
Loading...
News
all
press releases
Immuneering (IMRX) Expected to Announce Quarterly Earnings on Monday
Immuneering (NASDAQ:IMRX) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Immuneering (NASDAQ:IMRX) Upgraded at Wall Street Zen
Wall Street Zen raised Immuneering from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·17d ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com...
MarketBeat·19d ago
News Placeholder
Immuneering CEO Touts 64% 12-Month Survival in Pancreatic Cancer; Phase 3 Launch Nears
Immuneering (NASDAQ:IMRX) CEO Benjamin J. Zeskind told investors at a Needham conference session that 2026 has started with what he described as extraordinary early survival results for the company's...
MarketBeat·22d ago
News Placeholder
Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Immuneering from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·25d ago
News Placeholder
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts
Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendat...
MarketBeat·1mo ago
News Placeholder
Immuneering (IMRX) to Release Earnings on Thursday
Immuneering (NASDAQ:IMRX) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 19. (View Earnings Report at...
MarketBeat·2mo ago
News Placeholder
Immuneering's (IMRX) "Buy" Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued a "buy" rating and issued a $11.00 price objective on shares of Immuneering in a research note on Monday...
MarketBeat·2mo ago
News Placeholder
Immuneering (NASDAQ:IMRX) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Immuneering from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2mo ago
News Placeholder
Monashee Investment Management LLC Makes New Investment in Immuneering Corporation $IMRX
Monashee Investment Management LLC acquired a new stake in Immuneering Corporation (NASDAQ:IMRX - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and...
MarketBeat·2mo ago
<
1
2
...
>

Latest IMRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.